Abstract
No public abstract is available from the verified source records.
Xiaomei Leng, Lin Tang, Shanhui Ye, Xinwang Duan, Huaxiang Liu, Yongfu Wang, Mercedes Bustamante, Sharonjeet Kaur, Pellet Pascale, Xiaofeng Zeng
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists
10.1097/cm9.0000000000002683 · 2023
Clinical characteristics of psoriatic arthritis in chinese patients: A cross-sectional study
10.1007/s40744-021-00384-y · 2021
Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
10.1097/cm9.0000000000001710 · 2021
Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies
10.3390/ijms241210305 · 2023
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
10.1016/j.pharmthera.2021.107925 · 2022
Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: Update on integrated pooled clinical trial and post-marketing surveillance data
10.2340/actadv.v102.563 · 2022
Secukinumab: A review in psoriatic arthritis
10.1007/s40265-021-01476-3 · 2021
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/s0140-6736(15)61134-5 · 2015
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)
10.1186/s13075-018-1551-x · 2018
Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: Results from the FUTURE 4 study
10.1007/s40744-019-0163-5 · 2019
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study
10.1136/annrheumdis-2017-212687 · 2018
Safety of secukinumab from 1 million patient-years of exposure: Experience from post-marketing setting and clinical trials
10.1007/s13555-024-01122-2 · 2024
No additional external references are available.